NCT02431351View on ClinicalTrials.gov

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2019

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Selinexor

60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.

Sponsors
All Listed Sponsors
lead

Karyopharm Therapeutics Inc

INDUSTRY